Suplementos nutricionais no Transtorno do Espectro Autista: um relato de caso

Contenido principal del artículo

Sabrina dos Santos Serafim Fogaça
Marina Raijche Mattozo Rover

Resumen

Introdução: Estudos apontaram que o uso de suplementos nutricionais pode trazer grandes benefícios na redução dos sintomas do Transtorno do Espectro Autista (TEA). Além disso, sabe-se que os medicamentos aprovados para uso no tratamento do TEA proporcionam alívio parcial dos sintomas e podem ocasionar dependência física e/ou psíquica, além de importantes reações adversas. Objetivos: Relatar os benefícios da prescrição de suplementos para um paciente pediátrico com TEA, durante intervenção realizada por farmacêutico. Métodos: Após consentimento dos responsáveis, os dados registrados no sistema do estabelecimento de saúde foram analisados. Os dados apresentados referem-se ao período de outubro de 2021 até março de 2022. Os principais dados analisados foram: diagnóstico, sintomas, comorbidades associadas e tratamentos realizados. Resultados: O caso selecionado refere-se a um paciente de 10 anos de idade diagnosticado com TEA severo há 8 anos. No atendimento farmacêutico as principais intervenções foram: orientações sobre o uso de medicamentos e prescrição de suplementos, como vitaminas, aminoácidos, ácidos graxos, minerais e antioxidantes. Os principais benefícios observados foram: melhora da cognição, interação social e sensibilidade à luz; redução da irritabilidade, agitação, constipação; melhora do sono e no desenvolvimento da fala. Para tal avaliação utilizou-se instrumentos como ferramenta ATEC e relatos da responsável pelo paciente. Conclusão: A suplementação no TEA pode melhorar sintomas como transtornos gastrointestinais, distúrbios do sono e funções cognitivas. Neste relato de caso o paciente apresentou melhoras significativas nos sintomas após intervenção farmacêutica com a prescrição de fórmulas manipuladas.

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Cómo citar
dos Santos Serafim Fogaça, S., & Raijche Mattozo Rover, M. (2024). Suplementos nutricionais no Transtorno do Espectro Autista: um relato de caso. Revista Brasileira Multidisciplinar, 27(2), 210-223. https://doi.org/10.25061/2527-2675/ReBraM/2024.v27i2.1674
Sección
Relato de Caso
Biografía del autor/a

Sabrina dos Santos Serafim Fogaça, Universidade Federal de Santa Catarina

Universidade Federal de Santa Catarina. Programa de Pós Graduação em Assistência Farmacêutica – PPGASFAR. Florianópolis/SC, Brasil.

Marina Raijche Mattozo Rover, Universidade Federal de Santa Catarina

Universidade Federal de Santa Catarina. Programa de Pós Graduação em Assistência Farmacêutica – PPGASFAR. Florianópolis/SC, Brasil.

Citas

ADAMS, Jb; AUDHYA, T; GEIS, E; GEHN, E; FIMBRES, V; POLLARD, El; MITCHELL, J; INGRAM, J; HELLMERS, R; LAAKE, D; MATTHEWS, Js; LI, K; NAVIAUX, Jc; NAVIAUX, Rk; ADAMS, Rl; COLEMAN, Dm; QUIG, Dw. Comprehensive Nutritional and Dietary Intervention for Autism Spectrum Disorder-A Randomized, Controlled 12-Month Trial. Nutrients, v. 10, n. 3, p. 1-43, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872787/pdf/nutrients-10-00369.pdf. Acesso em: 05 de out. de 2022.

ARABA, B; MARRAFA, C. Short-term aripiprazole therapy for autismspectrum disorderAripiprazole for autism spectrum disorders (ASD). Journal of Paediatrics and Child Health, v. 54, n. 12, p. 1389-1391. 2018. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/jpc.14268. Acesso em: 15 de dez. de 2022.

Autism Treatment Evaluation Checklist (ATEC). Disponível em: https://www.autism.org/autism-treatment-evaluation-checklist. Acesso em: 09 de out. 2022.

BENT, S; HENDREN, Rl; ZANDI, T; LAW, K; CHOI, J-e; WIDJAJA, F; KALB, L; NESTLE, J; LAW, P. Internet-Based, Randomized Controlled Trial of Omega-3 Fatty Acids for Hyperactivity in Autism. Journal of the American Academy of Child and Adolescent Psychiatry, v. 53, n. 6, p. 658-666. 2014. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076340/pdf/nihms587642.pdf. Acesso em: 06 de nov. de 2022.

BORGES, Bka; FONSECA, Bsl; SILVA, Jf; COSTA, Vrf; SOARES, Wd. Farmacoterapia em crianças e adolescentes portadores de Transtorno do Espectro Autista - TEA. Revista Bionorte, v. 8, n. 2, p. 11-21. 2019. Disponível em: https://www.revistabionorte.com.br/arquivos_up/artigos/a155.pdf. Acesso em 02 de out. de 2022.

BRASIL. Ministério da saúde. Conitec. Protocolo Clínico e Diretrizes Terapêuticas do Comportamento Agressivo no Transtorno do Espectro do Autismo. Brasília-DF, 2021. 104 p.

CIPOLLA, Cm; LODHI, Ij. Peroxisomal Dysfunction in Age-Related Diseases. Trends in Endocrinology and Metabolism, v. 28, n. 4, p.: 297–308, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366081/pdf/nihms837298.pdf. Acesso em: 12 de out. de 2022.

CORDIOLI, Av; KIELING, C; SILVA, Ctb; PASSOS, Ic; BARCELOS, Mt. Manual Diagnóstico e Estatístico de Transtornos Mentais: DSM-V. 5. ed. Porto Alegre: Artmed; 2014. 848 p.

CUCINOTTA, F; RICCIARDELLO, A; TURRIZIANI, L; MANCINI, A; KELLER, R; SACCO, R; PERSICO, Am. Efficacy and Safety of Q10 Ubiquinol With Vitamins B and E in Neurodevelopmental Disorders: A Retrospective Chart Review. Frontiers in Psychiatry, v. 13, p. 1-10. 2022. Disponível em: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.829516/full. Acesso em: 16 de dez. de 2022.

CUCIUREANU Md; VINK, R. Magnesium in the Central Nervous System. Magnesium and stress. Adelaide (AU): University of Adelaide Press; 2011. 46 p. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK507250/. Acesso em 18 de dez. de 2022.

DEVANE, Cl; CHARLES, Jm; ABRAMSON, Rk; WILLIAMS, Je; CARPENTER, La; RAVEN, S; GWYNETTE, F; STUCK, Ca; GEESEY, Me; BRADLEY, C; DONOVAN, Jl; HALL, Ag; SHERK, St; POWERS, Nr; SPRATT, E; KINSMAN, A; KRUESI, Mj; JR, Jeb. Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial. Pharmacotherapy, v 39, n 6, p. 626-635. 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555676/pdf/nihms-1028157.pdf. Acesso em 15 de nov. de 2022.

DOAEI, S; BOURBOUR, F; TEYMOORI, Z; JAFARI, F; KALANTARI, N; TORKI, Sa; ASHOORI, N; GORGANI, Sn; GHOLAMALIZADEH, M. The effect of omega-3 fatty acids supplementation on social and behavioral disorders of children with autism: a randomized clinical trial. Pediatric Endocrinology Diabetes and Metabolism, v. 25, n. 1, p. 12–18. 2021. Disponível em: https://www.termedia.pl/The-effect-of-omega-3-fatty-acids-supplementation-on-social-and-behavioral-disorders-of-children-with-autism-a-randomized-clinical-trial,138,42737,1,1.html. Acesso em: 10 de out. de 2022.

DOMINIAK, A; WILKANIEC, A; JĘŚKO, H; CZAPSKI, A; LENKIEWICZ, Am; KUREK, E; WROCZYŃSKI, P; ADAMCZYK, A. Selol, an organic selenium donor, prevents lipopolysaccharide-induced oxidative stress and inflammatory reaction in the rat brain. Neurochemistry International, v 108, p. 66-77. 2017. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S019701861630331X?via%3Dihub. Acesso em: 26 de out. de 2022.

GEIER, Da; KERN, Jk; DAVIS, G; KING, Pg; ADAMS, Jb; YOUNG, Jl; GEIER, Mr. A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Medical Science Monitor, v. 17, n. 6, p. 15-23. 2011. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539542/pdf/medscimonit-17-6-pi15.pdf. Acesso em: 21 de nov. de 2022.

GOGOU, M; KOLIOS, G. The effect of dietary supplements on clinical aspects of autism spectrum disorder: A systematic review of the literature. Brain & Development, v 39, n 8, p. 656–664. 2017. Disponível em: https://www.brainanddevelopment.com/article/S0387-7604(17)30113-4/fulltext. Acesso em: 04 de dez. de 2022.

KEIM, As; JUDE, A; SMITH, K; KHAN, Aq; COURY, Dl; RAUSCH, J; UDAIPURIA, S; NORRIS, M; BARTRAM, Lr; NARAYANAN, A; ROGERS, Lk. Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum. Journal of Autism and Developmental, v. 52, p. 5342–5355. 2022. Disponível em: https://link.springer.com/content/pdf/10.1007/s10803-021-05396-9.pdf?pdf=button. Acesso em 04 de dez. de 2022.

KEPKA, A; OCHOCI ´NSKA, A; CHOJNOWSKA, S; BORZYM-KLUCZYK, M; SKORUPA, E; KNA´S, M; WASZKIEWICZ, N. Potential Role of L-Carnitine in Autism Spectrum Disorder. Journal of Clinical Medicine, v. 10, p. 1-26. 2021. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000371/pdf/jcm-10-01202.pdf. Acesso em: 21 de nov. de 2022.

KĘPKA, A; OCHOCIŃSKA, A; CHOJNOWSKA, S; BORZYM-KLUCZYK, M;

KHANNA, R; JARIWALA, K. Awareness and knowledge of autism among pharmacists. Research in Social and Administrative Pharmacy, v. 8, n. 5, p. 464-471, 2012. Disponível em: https://www.sciencedirect.com/journal/research-in-social-and-administrative-pharmacy/vol/8/issue/5. Acesso em: 02 de out. de 2022.

KIM, S.-J; SHONKA, S; FRENCH, Wp; STRICKLAND, J; MILLER, L; STEIN, Ma. Dose-response effects of long-acting liquid methylphenidate in children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): a pilot study. Journal of Autism and Developmental Disorders, v. 47, n. 8, p. 2307-2313. 2017. Disponível em: https://link.springer.com/article/10.1007%2Fs10803-017-3125-1. Acesso em: 25 de nov. de 2022.

KIRKLAND, Ae; SARLO, Gl; HOLTON, Kf. The Role of Magnesium in Neurological Disorders. Nutrients, v. 10, p. 1-23. 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024559/pdf/nutrients-10-00730.pdf. Acesso em: 17 de dez. de 2022.

KUWABARA, H; YAMASSUE, H; KOIKE, S; INOUE, H; KAWAKUBO, Y; KURODA, M; TAKANO, Y; IWASHIRO, N; NATSUBORI, T; AOKI, Y; KANO, Y; KASAI, K. Altered Metabolites in the Plasma of Autism Spectrum Disorder: A Capillary Electrophoresis Time-of-Flight Mass Spectroscopy Study. Plos One, v. 8, n. 9, p. 1-8. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776798/pdf/pone.0073814.pdf. Acesso em: 20 de dez. de 2022.

LEE, T-m; LEE, K-m; LEE, C-y; LEE, H-c; TAM, K-w; LO, E-w. Effectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trials. Australian & New Zealand Journal of Psychiatry, v. 55, n. 2, p. 1-11. 2021. Disponível em: https://journals.sagepub.com/doi/pdf/10.1177/0004867420952540. Acesso em 14 de dez. de 2022.

LIU, J; LIU, X; XIONG, X-Q; YANG, T; CUI, T; HOU, N-L; LAI, X; LIU, S; GUO, M; LIANG, X-H; CHENG, Q; CHEN, J; LI, T-Y. Effect of vitamin A supplementation on gut microbiota in children with autism spectrum disorders - a pilot study. BMC Microbiology, v 17, p. 1-14. 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610466/pdf/12866_2017_Article_1096.pdf. Acesso em: 05 de dez. de 2022.

LIU, X; LIN, J; ZHANG, H; KHAN, Nu; ZHANG, J; TANG, X; CAO, X; SHEN, L. Oxidative Stress in Autism Spectrum Disorder—Current Progress of Mechanisms and Biomarkers. Frontiers in Psychiatry, v. 13, p. 1-20. 2022. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921264/pdf/fpsyt-13-813304.pdf. Acesso em: 20 de nov. de 2022.

LOPES Damg. Atenção farmacêutica e consultórios farmacêuticos. Revista acadêmica Faculdades Oswaldo Cruz, n. 16 p. 1-9. 2017. Disponível em: https://oswaldocruz.br/revista_academica/content/pdf/Edicao_16_LOPES_Denise_Aparecida_Moreira_Gollner.pdf. Acesso em: 09 jun 2022.

MAHAPATRA, S; KHOKHLOVICH, E; MARTINEZ, S; KANNEL, B; EDELSON, Sm; VYSHEDSKIY, A. Longitudinal Epidemiological Study of Autism Subgroups Using Autism Treatment Evaluation Checklist (ATEC) Score. Journal of Autism and Developmental Disorders, v. 50, n. 5, p. 1497–1508. 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211200/pdf/10803_2018_Article_3699.pdf. Acesso em: 20 de dez. de 2022.

MALAGUARNERA, M; CAULI, O. Effects of l-Carnitine in Patients with Autism Spectrum Disorders: Review of Clinical Studies. Molecules, v 24, p. 1-10. 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930613/pdf/molecules-24-04262.pdf. Acesso em: 12 de out. de 2022.

MARTÍNEZ-GONZÁLEZ, Ae; ANDREO-MARTÍNEZ, P. Prebiotics, probiotics and fecal microbiota transplantation in autism: A systematic review. Revista de Psiquiatría y Salud Mental (English Edition), v 13, n 3, p. 150-164. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S1888989120300719. Acesso em: 03 de dez. de 2022.

MAZAHERY, H; CONLON, Ca; BECK, Kl; MUGRIDGE, O; KRUGER, Mc; STONEHOUSE, W; JR, Cac; MEYER, Bj; TSANG, B; JONES, B; HURST, Prv. A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder. Journal of Autism and Developmental Disorders, v 49, p. 1778-1794. 2019. Disponível em: https://link.springer.com/content/pdf/10.1007/s10803-018-3860-y.pdf?pdf=button. Acesso em: 13 de dez. de 2022.

MAZAHERY, H; JR, Cac; CONLON, C; BECK, Kl; KRUGER, Mc; HURSY, Prv. Vitamin D and Autism Spectrum Disorder: A Literature Review. Nutrients, v. 8, n. 4, p. 1-35. 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848704/pdf/nutrients-08-00236.pdf. Acesso em: 18 de out. de 2022.

MOUSAVINEJAD, E; GHAFFARI, Ma; RIAHI, F; HAJMOHAMMADI, M; TYZNOBEYK, Z; MOUSAVINEJAD, M. Coenzyme Q10 supplementation reduces oxidative stress and decreases antioxidant enzyme activity in children with autism spectrum disorders. Psychiatry Research, v. 265, p. 62-69. 2018. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0165178117317869?via%3Dihub. Acesso em 20 de nov. de 2022.

NAMVARPOUR, Z; NASEHI, M; AMINI, A; ZARRINDAST, Mr. Protective role of alpha-lipoic acid in impairments of social and stereotyped behaviors induced by early postnatal administration of thimerosal in male rat. Neurotoxicology and Teratology, v. 67, p. 1-9. 2018. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0892036217300867?via%3Dihub. Acesso em: 21 de nov. de 2022.

PANGRAZZI, L; BALASCO, L; BOZZI, Y. Natural Antioxidants: A Novel Therapeutic Approach to Autism Spectrum Disorders? Antioxidants, v. 9, p. 1-17. 2020. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761361/pdf/antioxidants-09-01186.pdf. Acesso em: 15 de dez. de 2022.

PEARSON, Da; SANTOS, Cw; AMAN, Mg; ARNOLD, Le; CASAT, Cd; MANSOUR, R; LANE, Dm; LOVELAND, Ka; BUKSTEIN, Og; JERGER, Sw; FACTOR, P; VANWOERDEN, S; PEREZ, E; CLEVELAND, La. Effects of Extended Release Methylphenidate Treatment on Ratings of Attention-Deficit/Hyperactivity Disorder (ADHD) and Associated Behavior in Children with Autism Spectrum Disorders and ADHD Symptoms. Journal of Child and Adolescent Psychopharmacoly, v. 23, n. 5, p. 337-351. 2013. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689935/pdf/cap.2012.0096.pdf. Acesso em: 21 de dez. de 2022.

PISACANE, R; SALVO, M. Pharmaceutical update on autism and its management. U.S. Pharmacist, v. 38, n. 1, p. 19-22, 2013. Disponível em: https://www.uspharmacist.com/article/pharmacist-update-on-autism-and-itsmanagement. Acesso em: 10 de out. de 2022.

ROSE, S; BENNURI, Sc; MURRAY Kf; BUIE, T; WINTER, H; FRYE, Re. Mitochondrial dysfunction in the gastrointestinal mucosa of children with autism: A blinded case-control study. Plos one, v. 12, n. 10, p. 1-19, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640251/pdf/pone.0186377.pdf. Acesso em: 02 de out. 2022.

SHARMA, Sr; GONDA, X; TARAZI, Fi. Autism Spectrum Disorder: Classification, diagnosis and therapy. Pharmacology & Therapeutics, v. 190, p. 91-104, 2018. Disponível em: https://www.sciencedirect.com/journal/pharmacology-and-therapeutics/vol/190/suppl/C. Acesso em: 30 de set. de 2022.

SKALNY, Av; SIMASHKOVA, Nv; SKALNAYA, Aa; KLYUSHNIK, Tp; ZHEGALOVA, Iv; GRABEKLIS, Ar; SKALNAYA, Mg; TINKOV, Aa. Trace element levels are associated with neuroinflammatory markers in children with autistic spectrum disorder. Journal of Trace Elements in Medicine and Biology, v. 50, p. 622–628. 2018. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0946672X18300324?via%3Dihub. Acesso em: 17 de dez. de 2021.

SKORUPA, E; KNAŚ, M; WASZKIEWICZ, N. Potential Role of L-Carnitine in Autism Spectrum Disorder. Journal of Clinical Medicine, v 10, p. 1-26. 2021. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000371/pdf/jcm-10-01202.pdf. Acesso em: 12 de out. de 2022.

STEPANOVA, E; DOWLING, S; PHELPS, M; FINDLING, Rl. Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Dialogues in Clinical Neuroscience, v. 19, n. 4, p. 395-402. 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789216/pdf/DialoguesClinNeurosci-19-395.pdf. Acesso em: 04 de dez. de 2022.

WU, H; ZHAO, G; LIU, S; ZHANG, Q; WANG, P; CAO, Y; WU, L. Supplementation with selenium attenuates autism-like behaviors and improves oxidative stress, inflammation and related gene expression in an autism disease model. The Journal of Nutritional Biochemistry, v. 107, p. 1-13. 2022. Disponível em: https://reader.elsevier.com/reader/sd/pii/S095528632200105X?token=A3FE74FCA03076092E12E19EDD45946E5280F4D5A91C292594D53DBD7409CF7EF0298FB9271BB8FE6B60BCA1513BAE99&originRegion=us-east-1&originCreation=20230106191515. Acesso em: 14 de dez. de 2022.